SHR4640 plus 40 mg febuxostat for primary gout and high uric acid

A Multicenter, Randomized, Double-blind, Active-controlled Parallel-group Phase ii Clinical Study to Compare the Efficacy and Safety of SHR4640 Tablets Combined With Febuxostat Tablets at 40 mg/Day Versus Febuxostat Tablets With Dose Escalation in Treatment of Primary Gout and Hyperuricemia Subjects With Inadequate Control on 40 mg/Day Febuxostat

This trial will test whether adding SHR4640 to a daily 40 mg febuxostat pill lowers uric acid in adults with primary gout who still have high uric acid on 40 mg febuxostat.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 340 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. (Industry-sponsored)
• Drugs / interventions: chemotherapy
• Locations: 1 site (Shanghai, Shanghai Municipality)
• Trial ID: NCT07362355 on ClinicalTrials.gov

What this trial studies

This Phase 2 interventional study compares SHR4640 tablets combined with 40 mg/day febuxostat against 60 mg/day febuxostat in adults with primary gout and persistent hyperuricemia. Eligible participants must have been on a stable 40 mg/day febuxostat dose for at least six weeks and meet defined serum uric acid thresholds and ACR/ACR-EULAR gout criteria. Participants receive the assigned treatment and are followed for 12 weeks with measurements of serum uric acid and monitoring for safety and tolerability. The trial is sponsored by Jiangsu HengRui Medicine and conducted at Huashan Hospital, Fudan University in Shanghai.

Who should consider this trial

Good fit: Adults 18–75 years old with primary gout and sustained hyperuricemia despite at least six weeks on 40 mg/day febuxostat, meeting ACR/ACR-EULAR gout criteria and with BMI 18–35 kg/m², are ideal candidates.

Not a fit: People whose uric acid is already controlled on their current therapy or who do not meet the run-in uric acid or medication-stability requirements are unlikely to gain benefit from this protocol.

Why it matters

Potential benefit: If successful, the combination could lower uric acid more effectively than increasing febuxostat dose, potentially reducing gout flares and long-term joint damage.

How similar studies have performed: Previous trials combining URAT1 inhibitors with xanthine oxidase inhibitors have shown uric acid lowering, but SHR4640 is a newer URAT1 agent and its combination with febuxostat is still being studied.

Eligibility criteria

Inclusion Criteria:

1. Voluntarily signed the informed consent, understood the procedures and methods of the study, and was willing to complete the study strictly in accordance with the clinical trial protocol;
2. The screening age should be 18-75 years old (including both ends), male or female;
3. Receive febuxostat at a stable dose of 40 mg/day for ≥6 weeks before randomization; have a fasting serum uric acid level ≥390 µmol/L at the first measurement, and a repeat fasting serum uric acid level ≥360 µmol/L after taking febuxostat 40 mg/day stably for ≥2 weeks during screening and run-in period,;
4. Meet the gout classification criteria formulated by the American College of Rheumatology (ACR) in 1977 or the joint gout classification criteria formulated by the American College of Rheumatology and the European League Against Rheumatism (ACR/EULAR) in 2015;
5. Body Mass Index (BMI) between 18 kg/m² and 35 kg/m².

Exclusion Criteria:

\-

Subjects who meet any of the following conditions will be excluded:

1\. General conditions:

1. Pregnant or lactating women;
2. Females of childbearing potential or males (except those whose partners are infertile) who refuse to use or use medically unapproved highly effective contraceptive measures within 6 months (for females) or 3 months (for males) from screening to the last dose of study medication;
3. Average daily alcohol intake exceeding 14 g for females (e.g., 145 mL of wine, 497 mL of beer, or 43 mL of low-alcohol liquor) or exceeding 28 g for males (e.g., 290 mL of wine, 994 mL of beer, or 86 mL of low-alcohol liquor) within 1 month before screening;
4. Drug abusers;
5. Subjects with poor compliance judged by investigators, which may affect the safety and efficacy evaluation of the study drug.

2\. The following laboratory abnormalities within 4 weeks before randomization:

1. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) and/or total bilirubin (TBIL) \> 2 times the upper limit of normal (ULN);
2. Estimated glomerular filtration rate (eGFR) \< 60 mL/(min×1.73m²) calculated by the Modification of Diet in Renal Disease (MDRD) formula based on serum creatinine level;
3. Glycated hemoglobin (HbA1c) ≥ 8%;
4. Active hepatitis B \[positive hepatitis B surface antigen (HBsAg) and hepatitis B virus deoxyribonucleic acid (HBV-DNA) exceeding the normal range\], or positive anti-hepatitis C virus (HCV) antibody, or positive human immunodeficiency virus (HIV) antibody, or positive syphilis antibody test;
5. White blood cell count \< 3.0×10⁹/L, and/or hemoglobin \< 90 g/L, and/or platelet count \< 80×10⁹/L;
6. Prolonged QTcF interval confirmed by repeated 12-lead electrocardiogram (ECG) (QTcF \> 450 ms).

3\. History of or comorbidities with any of the following:

1. Hypersensitivity to SHR4640 or any component of SHR4640, or a history of intolerance or contraindication to febuxostat or citrate;
2. Secondary hyperuricemia caused by tumors, chronic kidney disease, hematological diseases, drugs, or other causes;
3. Other joint lesions that investigators believe may confuse gouty arthritis, such as rheumatoid arthritis, suppurative arthritis, traumatic arthritis, psoriatic arthritis, pseudogout, systemic lupus erythematosus, or joint lesions caused by chemotherapy, radiotherapy, chronic lead poisoning, acute obstructive nephropathy, etc.;
4. B-ultrasound suggesting or suspecting urinary calculi within 4 weeks before randomization;
5. Gout flare within 2 weeks before randomization;
6. History of active peptic ulcer within 1 year before screening and during the screening period, or active peptic ulcer at screening;
7. History of xanthinuria;
8. Suffering from malignant tumors, or a history of malignant tumors within 5 years before screening (except for treated non-melanoma skin cancers with no signs of recurrence and resected cervical intraepithelial neoplasia);
9. History of chronic or recurrent infections within 1 year before screening and during the screening period; or severe infections (including but not limited to hepatitis, sepsis, pneumonia, pyelonephritis, etc.) or infections leading to hospitalization within 3 months before screening and during the screening period; or infections treated with intravenous antibiotics within 2 weeks before randomization; or open draining wounds or ulcers at screening and during the screening period;
10. Subjects requiring systemic treatment with immunosuppressants;
11. Past or current moderate to severe congestive heart failure (New York Heart Association Class III or IV);
12. Myocardial infarction, unstable angina pectoris, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, transient ischemic attack, and other cardiovascular and cerebrovascular events leading to hospitalization within 1 year before screening and during the screening period;
13. Poorly controlled hypertension at screening and during the screening period \[resting systolic blood pressure (SBP) ≥ 180 mmHg and/or diastolic blood pressure (DBP) ≥ 110 mmHg, confirmed by re-examination\];
14. Complicated with other severe or poorly controlled diseases;
15. Major surgery performed within 3 months before screening and during the screening period, or failure to recover after surgery, or plan to undergo major surgery during the study;
16. Blood donation (or blood loss) with a volume ≥ 400 mL, or blood transfusion received within 3 months before screening and during the screening period;
17. Other conditions deemed inappropriate for participation in this study by investigators.

4\. Use of any of the following drugs or participation in clinical trials:

1. Participation in any clinical trial of investigational drugs (including investigational vaccines) and use of investigational drugs within 3 months before screening or within 5 half-lives of the investigational drug (whichever is longer);
2. Participation in any clinical trial of medical devices within 3 months before screening (excluding subjects who failed screening);
3. Use of other urate-lowering drugs (allopurinol, probenecid, benzbromarone, dotinurad, recombinant urate oxidase) within 4 weeks before screening;
4. Use of drugs that interact with febuxostat (theophylline, azathioprine, mercaptopurine) within 4 weeks before screening;
5. Daily aspirin dosage exceeding 100 mg or unstable dosage within 4 weeks before screening;
6. Use of any diuretics within 2 weeks before randomization;
7. Use of angiotensin II receptor blockers (e.g., losartan), calcium channel blockers (e.g., amlodipine), fibrate lipid-lowering drugs (e.g., fenofibrate), statin lipid-lowering drugs (e.g., atorvastatin), clofibrate, acetohexamide, or sodium-glucose cotransporter 2 (SGLT2) inhibitors (e.g., empagliflozin) with unstable dosages within 2 weeks before randomization.

Where this trial is running

Shanghai, Shanghai Municipality

• Huashan Hospital, Fudan University — Shanghai, Shanghai Municipality, China (Recruiting)

Study contacts

• Study coordinator: Haoshu Cui

Conditions Primary Gout and Hyperuricemia